Journals / Turkish Journal of Internal Medicine / 2022 / Cilt: 4 - Sayı: 4

Comparison of Hemophagocytic Lymphohistiocytosis Diagnostic Criteria in Malignancy-Associated Hemophagocytic Lymphohistiocytosis Patients

Pages
180–189
Publication Date
2022-10-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We need to develop more specific and accessible criteria, and grading systems for M-HLH diagnose.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background Fulfilling diagnostic criteria of hemophagocytic lymphohistiocytosis (HLH) is challenging due to unavailable laboratory tests.
📊
Key Findings & Data:Results The median age was 59 years.
💡
Conclusion & Impact:We need to develop more specific and accessible criteria, and grading systems for M-HLH diagnose.
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:hemophagocytic lymphohistiocytosis · malignancy · diagnosis

Abstract

Background Fulfilling diagnostic criteria of hemophagocytic lymphohistiocytosis (HLH) is challenging due to unavailable laboratory tests. Hence, we aimed to reveal malignancy-associated-HLH (M-HLH) patients in our center, which can not be reached in all tests. Material and Methods Nine patients with M-HLH were analyzed retrospectively. Results The median age was 59 years. The distribution of the underlying diseases was like diffuse large B cell lymphoma in 3 patients, acute myeloid leukemia in 2 patients, Hodgkin lymphoma in 2 patients, T cell non-Hodgkin lymphoma in 1 patient, and small cell lung cancer in 1 patient. According to HLH-2004 diagnostic criteria except for soluble CD25 and natural killer activity tests; one patient had 3/6, six patients had 5/6, two patients had 6/6 criteria while the median H-score was 258 at diagnosis. According to Tamamyan et al’s criteria; at the diagnosis, all patients had ≥7 (between 7-12) of 18 parameters. Patients fulfilled ≥5 parameters a median of 15 days (3-52 days) before the diagnosis and on that time six patients had 3/6 criteria of HLH-2004. 88.8% of the patients died. The median duration of survival was 8.5 days (1-18 days). Conclusions Unavailability of the tests in some countries and centers as in ours results in complications to fulfill 5 of 8 criteria and being delayed in diagnosis and treatment. We need to develop more specific and accessible criteria, and grading systems for M-HLH diagnose.

🔖

Cite This Article

KIRKIZLAR, H. O., KIRKIZLAR, T. A., DEMİRCİ, U., GULSARAN, S. K., BAS, V., UMİT, E., DEMİR, A. M. (2022). Comparison of Hemophagocytic Lymphohistiocytosis Diagnostic Criteria in Malignancy-Associated Hemophagocytic Lymphohistiocytosis Patients. Turkish Journal of Internal Medicine, Cilt: 4 - Sayı: 4, 180–189. https://ajindex.com/articles/808952

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Janka GE, Lehmberg K. Hemophagocytic syndromes--an update. Blood Rev. 2014 Jul
  2. 28(4):135-42. doi: 10.1016/j.blre.2014.03.002. George M. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014 Jun 12
  3. doi: 10.2147/JBM.S46255. Ehl S, Astigarraga I, von Bahr Greenwood T, Hines M, Horne AC, Ishii E et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018 Sep-Oct
  4. 6(5):1508-17. doi: 10.1016/j.jaip.2018.05.031. La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JAM, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019 Jun 6
  5. 133(23):2465-77. doi: 10.1182/blood.2018894618. Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, Yamamoto K, Horiuchi H, Takada K, Ohshima K, Nakamura S, Kinukawa N, Oshimi K, Kawa K. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007 Jul
  6. 86(1):58-65. doi: 10.1532/IJH97.07012. Machaczka M, Vaktnäs J, Klimkowska M, Hagglund H. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma. 2011 Apr
  7. 52(4):613-9. doi: 10.3109/10428194.2010.551153. Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, La Rosée P, Kantarjian HM. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 1
  8. 123(17):3229-40. doi: 10.1002/cncr.30826. Kim YR, Kim DY. Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults. Blood Res. 2021 Apr 30
  9. 56(S1):S17-S25. doi: 10.5045/br.2021.2020323. Lehmberg K, Nichols KE, Henter JI, Girschikofsky M, Greenwood T, Jordan M, Kumar A, Minkov M, La Rosée P, Weitzman S
  10. Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica. 2015 Aug
  11. 100(8):997-1004. doi: 10.3324/haematol.2015.123562. Noseda R, Bertoli R, Müller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients trea